190 related articles for article (PubMed ID: 9122740)
1. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Saltz L; Janik JE
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
3. Topotecan in the treatment of gynecologic cancer.
Coleman RL; Miller DS
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
[TBL] [Abstract][Full Text] [Related]
4. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
5. Review of phase I clinical studies with topotecan.
Rowinsky EK; Verweij J
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
[TBL] [Abstract][Full Text] [Related]
7. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
8. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
[TBL] [Abstract][Full Text] [Related]
9. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN
Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325
[TBL] [Abstract][Full Text] [Related]
11. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP
Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897
[TBL] [Abstract][Full Text] [Related]
12. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
Homesley HD; Hall DJ; Martin DA; Lewandowski GS; Vaccarello L; Nahhas WA; Suggs CL; Penley RG
Gynecol Oncol; 2001 Nov; 83(2):394-9. PubMed ID: 11606103
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
[TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.
Rodriguez M; Rose PG
Gynecol Oncol; 2001 Nov; 83(2):257-62. PubMed ID: 11606080
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
Tolcher AW; O'Shaughnessy JA; Weiss RB; Zujewski J; Myhand RC; Schneider E; Hakim F; Gress R; Goldspiel B; Noone MH; Brewster LR; Gossard MR; Cowan KH
Clin Cancer Res; 1997 May; 3(5):755-60. PubMed ID: 9815746
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
[TBL] [Abstract][Full Text] [Related]
18. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
[TBL] [Abstract][Full Text] [Related]
19. Long time therapy with topotecan in patients with recurrence of ovarian carcinoma.
Möbus V; Pfaff PN; Volm T; Kreienberg R; Kaubitzsch S
Anticancer Res; 2001; 21(5):3551-6. PubMed ID: 11848522
[TBL] [Abstract][Full Text] [Related]
20. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
